Iron indices: What do they really mean?

被引:59
作者
Coyne, D [1 ]
机构
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
关键词
i.v; iron; iron deficiency; anemia; serum ferritin; iron markers; inflammation-malnutrition;
D O I
10.1038/sj.ki.5000404
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Routine monitoring of body iron stores is an essential component of overall management for the patient on hemodialysis. Adequate iron levels are important for the prevention and treatment of iron-deficiency anemia, which is associated with reduced physical functioning, cardiovascular disease, and poor quality of life. Hemodialysis patients are at especially high risk for iron-deficiency anemia, owing to continuous blood losses and supraphysiologic levels of erythropoiesis driven by recombinant human erythropoietin therapy. Unfortunately, the accurate determination of iron status in these patients can be a challenging task which is made more difficult by inflammation, infections, and the large number of comorbid conditions that can affect commonly used indices of body iron stores. Despite their limitations, transferrin saturation (TSAT) and serum ferritin remain the cornerstones of iron status assessment. Because these values can be altered by a number of non-iron-related factors, it is necessary to go beyond these measures and draw upon additional sources of information to determine the patient's iron status. Other important factors to consider when assessing the need for iron therapy include evidence of underlying inflammatory processes that may block iron mobilization and distort the standard iron indices, the results of alternative iron indices, and the patient's recent history of iron administration. Frequently, the response to a gram of intravenous (i.v.) iron is a safe and effective way to determine the role of iron deficiency in the anemia of the problematic patient. The chronic inflammatory state associated with malnutrition and clinical or subclinical infections substantially increases the risk of misdiagnosing the patient with iron overload and may place the patient at risk of iron deficiency owing to inappropriate withdrawal of i.v. iron therapy. To avoid the risks of withholding iron therapy, the nephrologist must keep this relationship in mind whenever serum ferritin testing suggests replete iron stores, whereas TSAT testing suggests insufficient iron availability.
引用
收藏
页码:S4 / S8
页数:5
相关论文
共 50 条
  • [1] WHAT DO WE MEAN BY "HYPERHAEMOLYSIS" AND WHAT IS THE CAUSE?
    Garratty, G.
    TRANSFUSION MEDICINE, 2012, 22 (02) : 77 - 79
  • [2] Tardive dyskinesia and serum iron indices
    Wirshing, DA
    Bartzokis, G
    Pierre, JM
    Wirshing, WC
    Sun, A
    Tishler, TA
    Marder, SR
    BIOLOGICAL PSYCHIATRY, 1998, 44 (06) : 493 - 498
  • [3] Iron in Pregnancy - How Do We Secure an Appropriate Iron Status in the Mother and Child?
    Milman, Nils
    ANNALS OF NUTRITION AND METABOLISM, 2011, 59 (01) : 50 - 54
  • [4] Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease
    Lomer, Miranda C. E.
    Cook, William B.
    Jan-Mohamed, Hamid Jan B.
    Hutchinson, Carol
    Liu, Ding Yong
    Hider, Robert C.
    Powell, Jonathan J.
    BRITISH JOURNAL OF NUTRITION, 2012, 107 (12) : 1806 - 1811
  • [5] Diagnostic value of reticulocyte indices for the assessment of the iron status of cats with chronic kidney disease
    Betting, Adeline
    Schweighauser, Ariane
    Francey, Thierry
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2022, 36 (02) : 619 - 628
  • [6] The "Iron Tale"- iron indices and handgrip strength in community-dwelling adults
    Ho, Vanda
    Lee, Chun-Tsu
    Merchant, Reshma A.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (12) : 3025 - 3032
  • [7] Iron Supplementation in Nephrology and Oncology: What Do We Have in Common?
    Macdougall, Iain C.
    ONCOLOGIST, 2011, 16 : 25 - 34
  • [8] Iron and hepcidin as risk factors in atherosclerosis: what do the genes say?
    Galesloot, Tessel E.
    Janss, Luc L.
    Burgess, Stephen
    Kiemeney, Lambertus A. L. M.
    den Heijer, Martin
    de Graaf, Jacqueline
    Holewijn, Suzanne
    Benyamin, Beben
    Whitfield, John B.
    Swinkels, Dorine W.
    Vermeulen, Sita H.
    BMC GENETICS, 2015, 16
  • [9] Iron replacement therapy: do we need new guidelines?
    Nielsen, Ole Haagen
    Coskun, Mehmet
    Weiss, Guenter
    CURRENT OPINION IN GASTROENTEROLOGY, 2016, 32 (02) : 128 - 135
  • [10] Iron and hepcidin as risk factors in atherosclerosis: what do the genes say?
    Tessel E. Galesloot
    Luc L. Janss
    Stephen Burgess
    Lambertus A. L. M. Kiemeney
    Martin den Heijer
    Jacqueline de Graaf
    Suzanne Holewijn
    Beben Benyamin
    John B. Whitfield
    Dorine W. Swinkels
    Sita H. Vermeulen
    BMC Genetics, 16